430 related articles for article (PubMed ID: 32949500)
1. Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial.
Leitner L; Ujmajuridze A; Chanishvili N; Goderdzishvili M; Chkonia I; Rigvava S; Chkhotua A; Changashvili G; McCallin S; Schneider MP; Liechti MD; Mehnert U; Bachmann LM; Sybesma W; Kessler TM
Lancet Infect Dis; 2021 Mar; 21(3):427-436. PubMed ID: 32949500
[TBL] [Abstract][Full Text] [Related]
2. Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial.
Leitner L; Sybesma W; Chanishvili N; Goderdzishvili M; Chkhotua A; Ujmajuridze A; Schneider MP; Sartori A; Mehnert U; Bachmann LM; Kessler TM
BMC Urol; 2017 Sep; 17(1):90. PubMed ID: 28950849
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.
Jault P; Leclerc T; Jennes S; Pirnay JP; Que YA; Resch G; Rousseau AF; Ravat F; Carsin H; Le Floch R; Schaal JV; Soler C; Fevre C; Arnaud I; Bretaudeau L; Gabard J
Lancet Infect Dis; 2019 Jan; 19(1):35-45. PubMed ID: 30292481
[TBL] [Abstract][Full Text] [Related]
4. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials.
Wagenlehner F; Perry CR; Hooton TM; Scangarella-Oman NE; Millns H; Powell M; Jarvis E; Dennison J; Sheets A; Butler D; Breton J; Janmohamed S
Lancet; 2024 Feb; 403(10428):741-755. PubMed ID: 38342126
[TBL] [Abstract][Full Text] [Related]
5. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
[TBL] [Abstract][Full Text] [Related]
6. Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial.
Fisher H; Oluboyede Y; Chadwick T; Abdel-Fattah M; Brennand C; Fader M; Harrison S; Hilton P; Larcombe J; Little P; McClurg D; McColl E; N'Dow J; Ternent L; Thiruchelvam N; Timoney A; Vale L; Walton K; von Wilamowitz-Moellendorff A; Wilkinson J; Wood R; Pickard R
Lancet Infect Dis; 2018 Sep; 18(9):957-968. PubMed ID: 30037647
[TBL] [Abstract][Full Text] [Related]
7. Single-dose versus 3-day cotrimoxazole prophylaxis in transurethral resection or greenlight laser vaporisation of the prostate: study protocol for a multicentre randomised placebo controlled non-inferiority trial (CITrUS trial).
Speich B; Bausch K; Roth JA; Hemkens LG; Ewald H; Vogt DR; Bruni N; Deuster S; Seifert HH; Widmer AF
Trials; 2019 Feb; 20(1):142. PubMed ID: 30782183
[TBL] [Abstract][Full Text] [Related]
8. Sanjin tablets for acute uncomplicated lower urinary tract infection (syndrome of dampness-heat in the lower jiao): protocol for randomized, double-blind, double-dummy, parallel control of positive drug, multicenter clinical trial.
Lyu J; Xie YM; Gao Z; Shen JW; Deng YY; Xiang ST; Gao WX; Zeng WT; Zhang CH; Yi DH; Wang LX; Wang ZF
Trials; 2019 Jul; 20(1):446. PubMed ID: 31324199
[TBL] [Abstract][Full Text] [Related]
9. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
11. Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials.
Lockley SW; Dressman MA; Licamele L; Xiao C; Fisher DM; Flynn-Evans EE; Hull JT; Torres R; Lavedan C; Polymeropoulos MH
Lancet; 2015 Oct; 386(10005):1754-64. PubMed ID: 26466871
[TBL] [Abstract][Full Text] [Related]
12. Neomycin-polymyxin or gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on clean intermittent catheterization.
Huen KH; Nik-Ahd F; Chen L; Lerman S; Singer J
J Pediatr Urol; 2019 Apr; 15(2):178.e1-178.e7. PubMed ID: 30611650
[TBL] [Abstract][Full Text] [Related]
13. Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: the AnTIC RCT.
Pickard R; Chadwick T; Oluboyede Y; Brennand C; von Wilamowitz-Moellendorff A; McClurg D; Wilkinson J; Ternent L; Fisher H; Walton K; McColl E; Vale L; Wood R; Abdel-Fattah M; Hilton P; Fader M; Harrison S; Larcombe J; Little P; Timoney A; N'Dow J; Armstrong H; Morris N; Walker K; Thiruchelvam N
Health Technol Assess; 2018 May; 22(24):1-102. PubMed ID: 29766842
[TBL] [Abstract][Full Text] [Related]
14. Bacteriophages: a Panacea in Neuro-Urology?
Leitner L; Kessler TM; Klumpp J
Eur Urol Focus; 2020 May; 6(3):518-521. PubMed ID: 31732462
[TBL] [Abstract][Full Text] [Related]
15. An economic analysis of antimicrobial prophylaxis against urinary tract infection in patients undergoing transurethral resection of the prostate.
Liu GG; Nguyen T; Nichol MB
Clin Ther; 1999 Sep; 21(9):1589-604. PubMed ID: 10509853
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of GABA
Chabriat H; Bassetti CL; Marx U; Audoli-Inthavong ML; Sors A; Lambert E; Wattez M; Hermann DM;
Lancet Neurol; 2020 Mar; 19(3):226-233. PubMed ID: 32085836
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of a tailored intervention to reduce antibiotics for urinary tract infections in nursing home residents: a cluster, randomised controlled trial.
Arnold SH; Nygaard Jensen J; Bjerrum L; Siersma V; Winther Bang C; Brostrøm Kousgaard M; Holm A
Lancet Infect Dis; 2021 Nov; 21(11):1549-1556. PubMed ID: 34303417
[TBL] [Abstract][Full Text] [Related]
18. Bacteriophage therapy for
Bhargava K; Nath G; Dhameja N; Kumar R; Aseri GK; Jain N
Future Microbiol; 2023 Apr; 18():323-334. PubMed ID: 37140267
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Lafaurie M; Chevret S; Fontaine JP; Mongiat-Artus P; de Lastours V; Escaut L; Jaureguiberry S; Bernard L; Bruyere F; Gatey C; Abgrall S; Ferreyra M; Aumaitre H; Aparicio C; Garrait V; Meyssonnier V; Bourgarit-Durand A; Chabrol A; Piet E; Talarmin JP; Morrier M; Canoui E; Charlier C; Etienne M; Pacanowski J; Grall N; Desseaux K; Empana-Barat F; Madeleine I; Bercot B; Molina JM; Lefort A;
Clin Infect Dis; 2023 Jun; 76(12):2154-2162. PubMed ID: 36785526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
